<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Saban MR</submitter><funding>NIDDK NIH HHS</funding><pagination>204</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2212656</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy. The objective of this study was to determine differentially expressed genes in the mouse bladder following repeated intravesical BCG therapy.&lt;h4>Methods&lt;/h4>Mice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21. Seven days after the last instillation, urothelia along with the submucosa was removed and amplified ds-DNA was prepared from control- and BCG-treated bladde</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.</pubmed_title><pmcid>PMC2212656</pmcid><funding_grant_id>5 R01 DK066101-02</funding_grant_id><funding_grant_id>R01 DK066101</funding_grant_id><funding_grant_id>R01 DK055828</funding_grant_id><funding_grant_id>5 R01 DK055828-05</funding_grant_id><pubmed_authors>O'Donnell MA</pubmed_authors><pubmed_authors>Wu XR</pubmed_authors><pubmed_authors>Saban MR</pubmed_authors><pubmed_authors>Hellmich HL</pubmed_authors><pubmed_authors>Simpson C</pubmed_authors><pubmed_authors>Lang ML</pubmed_authors><pubmed_authors>Ihnat MA</pubmed_authors><pubmed_authors>Saban R</pubmed_authors><pubmed_authors>Davis CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.</name><description>&lt;h4>Background&lt;/h4>Despite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy. The objective of this study was to determine differentially expressed genes in the mouse bladder following repeated intravesical BCG therapy.&lt;h4>Methods&lt;/h4>Mice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21. Seven days after the last instillation, urothelia along with the submucosa was removed and amplified ds-DNA was prepared from control- and BCG-treated bladde</description><dates><release>2007-01-01T00:00:00Z</release><publication>2007 Nov</publication><modification>2025-04-04T10:36:11.691Z</modification><creation>2019-03-27T02:43:51Z</creation></dates><accession>S-EPMC2212656</accession><cross_references><pubmed>17980030</pubmed><doi>10.1186/1471-2407-7-204</doi></cross_references></HashMap>